Is RENAL FAILURE a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed RENAL FAILURE.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 34 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported RENAL FAILURE to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and RENAL FAILURE. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause RENAL FAILURE, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes RENAL FAILURE. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if RENAL FAILURE ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing RENAL FAILURE: 34
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where RENAL FAILURE is a reported side effect: 1.0213%

FDA reports of any drug causing RENAL FAILURE : 56386
Average percentage for all medicated patients where RENAL FAILURE is reported as a complication: 0.3534%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with RENAL FAILURE:

TRASYLOL (12850 patients)
LASIX (5785 patients)
ASPIRIN (4998 patients)
HEPARIN (3807 patients)
VIOXX (3771 patients)
HEPARIN SODIUM INJECTION (3151 patients)
FUROSEMIDE (3005 patients)
LIPITOR (2609 patients)
LISINOPRIL (2416 patients)
DIGOXIN (2302 patients)
NITROGLYCERIN (2243 patients)
ALLOPURINOL (2196 patients)
PLAVIX (2048 patients)
COUMADIN (2024 patients)
PREDNISONE (2016 patients)
VANCOMYCIN (1862 patients)
FOSAMAX (1859 patients)
REVLIMID (1839 patients)
INSULIN (1823 patients)
PROTAMINE SULFATE (1774 patients)
ACETAMINOPHEN (1769 patients)
ZOCOR (1762 patients)
OMEPRAZOLE (1753 patients)
NORVASC (1681 patients)
SIMVASTATIN (1661 patients)
ACETYLSALICYLIC ACID SRT (1644 patients)
ATENOLOL (1624 patients)
POTASSIUM CHLORIDE (1564 patients)
ZOMETA (1542 patients)
RED BLOOD CELLS (1525 patients)
FENTANYL (1479 patients)
AVANDIA (1421 patients)
HYDROCHLOROTHIAZIDE (1410 patients)
NEXIUM (1405 patients)
VERSED (1339 patients)
DEXAMETHASONE (1331 patients)
METFORMIN HCL (1311 patients)
TOPROL-XL (1309 patients)
SEROQUEL (1300 patients)
LANTUS (1286 patients)
METHOTREXATE (1275 patients)
SYNTHROID (1252 patients)
PROTONIX (1234 patients)
FOLIC ACID (1156 patients)
NEURONTIN (1132 patients)
PREDNISOLONE (1129 patients)
COREG (1123 patients)
LEVAQUIN (1107 patients)
DIOVAN (1100 patients)
METOPROLOL TARTRATE (1097 patients)
CELEBREX (1089 patients)
LEVOTHYROXINE SODIUM (1076 patients)
PRILOSEC (1056 patients)
PLATELETS (1050 patients)
REMICADE (1007 patients)
SPIRONOLACTONE (999 patients)
AMLODIPINE (991 patients)
MORPHINE (980 patients)
AMIODARONE HCL (969 patients)
CRESTOR (962 patients)
CISPLATIN (943 patients)
ALBUTEROL (936 patients)
LOVENOX (928 patients)
LOPRESSOR (921 patients)
AREDIA (906 patients)
EPINEPHRINE (899 patients)
RAMIPRIL (894 patients)
ALDACTONE (891 patients)
IBUPROFEN (888 patients)
XANAX (887 patients)
HUMIRA (879 patients)
CYCLOPHOSPHAMIDE (872 patients)
AMBIEN (872 patients)
WARFARIN SODIUM (869 patients)
MANNITOL (863 patients)
PREVACID (851 patients)
LIDOCAINE (841 patients)
LORAZEPAM (840 patients)
DOPAMINE HCL (839 patients)
PREDNISONE TAB (828 patients)
ENALAPRIL MALEATE (822 patients)
BYETTA (808 patients)
GLUCOPHAGE (797 patients)
CYCLOSPORINE (792 patients)
ZYPREXA (752 patients)
ZOLOFT (746 patients)
ATIVAN (745 patients)
ANCEF (740 patients)
ZOFRAN (730 patients)
LYRICA (724 patients)
PROPOFOL (718 patients)
METOPROLOL (716 patients)
ALBUMIN (HUMAN) (715 patients)
COZAAR (714 patients)
TACROLIMUS (702 patients)
HEPARIN SODIUM (699 patients)
SODIUM BICARBONATE (688 patients)
AVONEX (687 patients)
HUMALOG (683 patients)
PROGRAF (675 patients)
CIPROFLOXACIN (666 patients)
OXYCONTIN (646 patients)
EXJADE (646 patients)
SOLU-MEDROL (644 patients)
PERCOCET (641 patients)
FORTEO (641 patients)
VELCADE (641 patients)
CLONIDINE (638 patients)
GABAPENTIN (635 patients)
FRESH FROZEN PLASMA (626 patients)
FLUCONAZOLE (623 patients)
DECADRON (622 patients)
GLYBURIDE (619 patients)
VICODIN (616 patients)
CYMBALTA (613 patients)
PAXIL (612 patients)
FLUOROURACIL (611 patients)
BACTRIM (594 patients)
ACTOS (589 patients)
GLIPIZIDE (581 patients)
ACYCLOVIR (579 patients)
CARVEDILOL (576 patients)
ALTACE (568 patients)
ENBREL (550 patients)
BISOPROLOL FUMARATE (546 patients)
MYCOPHENOLATE MOFETIL (544 patients)
MILRINONE (543 patients)
LEVOPHED (539 patients)
PANTOPRAZOLE (539 patients)
LEXAPRO (537 patients)
LANSOPRAZOLE (535 patients)
THALOMID (534 patients)
ZESTRIL (525 patients)
TRAMADOL HCL (522 patients)
ARANESP (521 patients)
CORDARONE (520 patients)
ZANTAC (518 patients)
OXYCODONE HCL (503 patients)
VITAMIN D (501 patients)
NEORAL (494 patients)
MAGNESIUM SULFATE (493 patients)
DURAGESIC-100 (490 patients)
ADVAIR DISKUS 100/50 (489 patients)
MORPHINE SULFATE (487 patients)
IMDUR (485 patients)
TRACLEER (483 patients)
CARBOPLATIN (482 patients)
PEPCID (480 patients)
PROZAC (480 patients)
ZETIA (478 patients)
LORTAB (470 patients)
ALPRAZOLAM (463 patients)
FERROUS SULFATE TAB (461 patients)
BENADRYL (455 patients)
CALCIUM (455 patients)
TORSEMIDE (453 patients)
CYTARABINE (450 patients)
ATORVASTATIN CALCIUM (450 patients)
METHYLPREDNISOLONE (443 patients)
GLEEVEC (443 patients)
CEFAZOLIN (437 patients)
FAMOTIDINE (435 patients)
MICARDIS (433 patients)
RISPERDAL (432 patients)
SPIRIVA (432 patients)
COLACE (431 patients)
EFFEXOR (429 patients)
MIDAZOLAM HCL (425 patients)
CELLCEPT (425 patients)
METOPROLOL SUCCINATE (422 patients)
AMOXICILLIN (420 patients)
CLONAZEPAM (420 patients)
PROCRIT (419 patients)
ROCEPHIN (415 patients)
AMARYL (410 patients)
CALCIUM CHLORIDE (407 patients)
REGLAN (406 patients)
AVELOX (405 patients)
FLOMAX (405 patients)
MULTI-VITAMINS (404 patients)
POTASSIUM (403 patients)
METFORMIN (402 patients)
PRADAXA (401 patients)
RANITIDINE (398 patients)
NIFEDIPINE (388 patients)
VYTORIN (388 patients)
COMPAZINE (385 patients)
DIFLUCAN (384 patients)
TRICOR (383 patients)
AMLODIPINE BESYLATE (382 patients)
ETOPOSIDE (379 patients)
KALETRA (376 patients)
FLAGYL (375 patients)
SINGULAIR (370 patients)
LANOXIN (370 patients)
GENTAMICIN (369 patients)
COLCHICINE (367 patients)
HYDROCORTISONE (367 patients)
METOCLOPRAMIDE (366 patients)
DILTIAZEM (365 patients)
KLOR-CON (364 patients)
CARDIZEM (362 patients)
PLASMA (361 patients)
JANUVIA (360 patients)
PANTOPRAZOLE SODIUM (359 patients)
PARACETAMOL (359 patients)
PRAVACHOL (358 patients)
TRAZODONE HCL (358 patients)
BUMEX (358 patients)
VINCRISTINE (358 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about RENAL FAILURE and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.